Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
Open Access
Abstract
Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance mutations in the clinic. We believe that this is due to the long binding time of DTG to the integrase enzyme as well as greatly diminished replication capacity on the part of viruses that might become resistant to DTG. We further speculate that DTG might be able to be used in strategies aimed at HIV eradication.Keywords
Funding Information
- Gilead Sciences
- Merck Inc.
- Viiv Healthcare Inc.
- Bristol-Myers Squibb
This publication has 18 references indexed in Scilit:
- Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacityJournal of Antimicrobial Chemotherapy, 2014
- Resistance to HIV integrase inhibitorsCurrent Opinion in HIV and AIDS, 2012
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialThe Lancet, 2012
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksThe Lancet, 2012
- Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor DolutegravirJournal of Virology, 2012
- Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyThe Lancet Infectious Diseases, 2012
- Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA ComplexesAntimicrobial Agents and Chemotherapy, 2011
- G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does notRetrovirology, 2011
- Development of Antiretroviral Drug ResistanceNew England Journal of Medicine, 2011
- Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1New England Journal of Medicine, 2000